Duke-NUS graduates biggest class yet, with new doctors drawn from business, engineering and the humanities
At his first graduation as Dean, Patrick Tan presides over a record class of 135 graduates, with Guest of Honour Mdm Rahayu Mahzam and keynote speaker Dr Robert Califf SINGAPORE, May 30, 2026 /PRNewswire/ -- From engineers and business graduates to literature and communications majors, Duke-NUS Medical School's largest graduating class to date reflects the widening range of backgrounds...
XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies
BOSTON, May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc. has achieved substantial progress, and that XtalPi has received the second payment under the agreement. Since the two parties entered into a collaboration...
Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering
SHANGHAI, May 29, 2026 /PRNewswire/ -- Zhongchao Inc. ("Zhongchao" or the "Company") (NASDAQ: ZCMD), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced the pricing of a best efforts public offering with gross proceeds to the Company expected to be approximately $5 million, before deducting placement agent fees and other...
Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions
SHANGHAI, May 29, 2026 /PRNewswire/ -- Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, today announced that new clinical data from the Phase IIb ENLIGHT study of Efsubaglutide alfa in overweight and obesity will be presented at the 2026 American Diabetes Association (ADA) Scientific Sessions, to be held...
Holmusk Expands NeuroBlu to 46 Million Patients, Adding Depth and Biomarker Data Across Neurology and Behavioral Health
Expansion anchored by two top neurological health systems, structured AD biomarker data, and validated outcomes measures across neurological disease areas. Whole-population ingestion shifts NeuroBlu from patient counts to research-grade signal. NEW YORK, May 29, 2026 /PRNewswire/ -- Holmusk today announced a major expansion of NeuroBlu, growing to over 46 million de-identified patient lives sourced from longitudinal EHR data -...
SKIA HEAD: AR Surgical Guidance Receives FDA 510(k) Clearance, Eyes U.S. Expansion with Structure Partnership
SEOUL, South Korea, May 29, 2026 /PRNewswire/ -- South Korea-based medtech innovator SKIA has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its augmented reality (AR) surgical guidance system, SKIA HEAD. This regulatory milestone clears the path for the system's commercial debut in the United States, supported by a strategic hardware partnership. SKIA...
Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins WU-KONG28 is the first global randomized phase 3 study with positive results for an oral, chemo-free, targeted monotherapy regimen in first-line EGFR exon20ins NSCLC Late-breaking data were presented at the 2026 ASCO...
CooperVision Names Muru Annamalai as President, Asia-Pacific
Experienced Global Healthcare Leader to Guide Growth Across the Region SINGAPORE, May 29, 2026 /PRNewswire/ -- CooperVision has named Muru Annamalai as President, Asia-Pacific, effective June 1. He brings more than two decades of global leadership experience across the pharmaceutical and healthcare sectors, with extensive expertise leading commercial organizations and driving...
SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund
SK bioscience's board approval follows the Financial Services Commission's May 28 announcement selecting the company as a beneficiary of the KRW 300 billion (approximately USD 230 million) Korea Growth Fund financing program SK bioscience became the first Korean novel drug and vaccine developer selected for the Korea Growth Fund, with the...
RingConn Gen 3 Smart Ring Officially Launches: Expanding Long-Term Health Awareness in Everyday Life
World's Leading Provider of Cutting-Edge Smart Ring Solutions NEW YORK, May 29, 2026 /PRNewswire/ -- RingConn officially launches the Gen 3 Smart Ring globally on May 29th, bringing vascular insights and continuous tracking into a refined ultra-lightweight wearable experience. Following pre-order earlier this month, early adopters of the device already include Grammy Award-winning artist Jessie J and athletes from...
